CDT Equity Inc. Announces Reverse Stock Split

Rhea-AI Summary

CDT Equity (Nasdaq: CDT) approved a 1-for-8 reverse stock split, effective Oct 10, 2025 at 5:00 pm ET, with post-split trading expected on Oct 13, 2025 on Nasdaq under the existing ticker CDT.

As of the Effective Time, every eight pre-split shares will be combined into one share, reducing outstanding common stock to approximately 1,352,448 shares. Par value remains $0.0001. Equity awards, convertible securities, warrants, and plan reserves will be proportionally adjusted. Fractional shares will not be issued; holders entitled to fractions will receive a proportional cash payment. The new CUSIP will be 20678X403. The board said the split is expected to increase the amount of funds the company might be able to raise. VStock Transfer, LLC will act as exchange agent.

Positive

• Reverse split ratio set at 1-for-8
• Expected outstanding shares post-split: ~1,352,448
• Company expects increased ability to raise funds
• Trading to resume on adjusted basis on Oct 13, 2025

Negative

• No fractional shares issued; entitled holders receive cash payments
• Reverse split may change per-share liquidity and trading dynamics after Oct 13, 2025

Insights

Corporate Actions Analyst

1-for-8 reverse split to reduce outstanding shares to ~1,352,448 and enable larger financing options.

The board approved a 1-for-8 reverse stock split effective October 10, 2025, with adjusted trading on Nasdaq at open on October 13, 2025, reducing outstanding shares to approximately 1,352,448 and creating a new CUSIP 20678X403. Equity awards, convertibles and warrants will be proportionally adjusted and fractional shares will be cashed out; registered and street-name holders need no action.

This action primarily changes share count and per‑share metrics rather than underlying business fundamentals; the board states the goal is to increase the amount of funds the company might raise. Key dependencies include market reception at the adjusted share level and actual capital‑raising activity following the split. Watch for any financing announcements or changes in authorized share counts within the next few months, and note the shareholder authorization granted on May 5, 2025 that enabled this move.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-8 reverse stock split of the Company’s common stock. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios, at the Company’s Special Meeting of Stockholders held on May 5, 2025. The directors expect that the reverse stock split will increase the amount of funds the Company might be able to raise to execute its strategy.

The reverse stock split will become effective on October 10, 2025, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “CDT” on October 13, 2025, the date which has been approved by Nasdaq for the effectiveness of such split.

As of the Effective Time, every eight shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at $0.0001. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants, as well as the applicable exercise price, and the number of shares authorized and reserved for issuance pursuant to the Company’s equity incentive plans.

The Company’s common stock will continue to trade on Nasdaq under the symbol “CDT” following the reverse stock split, with a new CUSIP number of 20678X403. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 1,352,448. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.

The Company’s transfer agent, VStock Transfer, LLC, will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com

FAQ

What is the reverse stock split ratio for CDT and when is it effective?

CDT is implementing a 1-for-8 reverse stock split effective Oct 10, 2025 at 5:00 pm ET.

When will CDT shares trade on a split-adjusted basis on Nasdaq?

CDT common stock is expected to trade on a split-adjusted basis on Nasdaq at market open on Oct 13, 2025 under the existing symbol CDT.

How many CDT shares will be outstanding after the reverse split?

After effectiveness, the number of outstanding common shares will be reduced to approximately 1,352,448.

Will CDT issue fractional post-split shares to stockholders?

No. CDT will not issue fractional shares; stockholders entitled to fractions will receive a proportional cash payment.

Will CDT adjust equity awards and warrants for the reverse split?

Yes. The number of shares issuable upon awards, convertibles, and warrants and their exercise prices will be proportionally adjusted.

What is CDT’s new CUSIP after the reverse split?

The post-split CUSIP for CDT common stock will be 20678X403.

Do CDT stockholders need to take action to receive post-split shares?

Registered holders in book-entry form and brokerage account holders generally do not need to take action; brokers will adjust positions per their processes.